Dataset opportunity
Acandis — 医疗影像数据集机会
Acandis 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2024 年为 17.0 亿美元，复合年增长率为 25.8%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Acandis 拥有一个极具价值的医疗影像数据集，专注于神经血管疾病，该数据集源于其作为中风治疗医疗设备开发商的活动。该集合结合了临床试验的原始影像数据与其神经血管植入物相关的专有研发绩效数据（`industrial_data`）以及相关的 `medical_records`，提供了一个丰富、多方面的数据资源，非常适合训练和验证诊断人工智能算法。
该数据的商业价值巨大，位于全球医疗影像人工智能市场内，该市场在 2024 年的估值为17.0 亿美元，预计将以惊人的 25.8% 的复合年增长率增长。虽然由于敏感的患者数据（PHI）、专有研发信息和严格的 MDR 治理，访问权限很复杂，但这种复杂性确保了数据集的异常详细和规范。这种临床和设备绩效数据的稀有组合使其成为寻求在快速增长的神经血管领域创建下一代诊断工具的人工智能开发者的优质资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床试验数据包含敏感的患者健康信息（PHI），需要严格匿名化；神经血管植入物绩效的专有研发数据高度专业化；受严格的医疗器械法规（MDR）数据治理约束 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Acandis 拥有一个专有的术前和术后神经影像数据集合，直接关联到正式临床试验的患者结果。该数据集是训练和验证用于中风评估的诊断人工智能模型的稀有资产。在一个年增长率超过 25% 的医疗影像人工智能市场中，这种高质量、与结果相关联的血管造影数据为开发下一代医疗影像解决方案提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
人工智能买家需求异常高，这得益于全球医疗影像人工智能市场 25.8% 的快速复合年增长率，该市场积极寻求高质量的专业数据集以推动创新。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ 良好目标 — Acandis 是一个良好目标，因为它是一家医疗设备制造商，其核心业务是销售用于中风治疗的实体产品，而不是数据或人工智能，这意味着来自临床试验或设备使用的任何运营影像数据都可能是一个潜在的休眠副产品。问题：主要问题是数据所有权；虽然 Acandis 的设备用于产生医疗影像的手术，但这些数据主要由 t 创建和存储；公司拥有 300 名员工，属于中型企业定义的较大一侧（通常 <250），这可能会影响谈判动态。[1, 5]
- Deep Qualification90
✓ 通过 — Acandis 是一家神经血管疾病医疗设备开发商，使其成为宝贵的临床试验数据（包括医疗影像）的数据持有者。这些数据是其核心业务的副产品。由于临床研究的性质，所有权是混合的，并且由于医疗数据法规（GDPR）的限制，转售许可受到高度限制。最近的一个触发因素是 2026 年 8 月批准启动一项新的关键性临床试验（SONIC），该试验将产生新的、有价值的数据。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
Acandis 持有其正式临床研究的纵向患者结果数据，提供了训练和验证监督学习模型所需的关键真实标签。
Industrial data
该公司维护其 III 类医疗设备的详细研发和制造记录，证明了其所有运营都秉持着严格的、监管机构强制要求的数据纪律。
Image collection
这证实了核心资产：在用于中风治疗设备的临床试验中生成的大量术前和术后血管造影和神经影像扫描。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Acandis Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market = $1.70B in 2024, CAGR 25.8% (source: Market.us). Investment score 68.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Bellaseno — Medical Imaging Dataset Opportunity
View opportunity →mobilityLashing — Inspection Reports Dataset Opportunity
View opportunity →industrialBauwatch — Industrial Sensor Dataset Opportunity
View opportunity →